ARCHIVES

Perifosine Fails Primary Endpoint, Zentaris CEO Explores Options

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

Cancer Drugs Initiatives To Shorten approval Times, Ensure Post-Marketing Studies, FDA Official Says

April 26, 1996

Large Phase III Trial Seeks Optimal Use Of Tykerb vs. Herceptin In Breast Cancer

February 29, 2008

Analysis Finds Exercise Lowers Colon Cancer Risk

February 27, 2009

Includes May issue of Business & Regulatory Report.

May 31, 2002

Cancer Letter Adds Associate Editor

July 19, 1985

U. Arizona Center Finds a Way To Community Rapport

January 18, 1980